title: A diagnostic dilemma in stem cell transplantation for beta-thalassemia major: progressive loss of take or pure red cell aplasia?
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Visani
authors.forename: Moira
authors.initials: M
authors.lastname: Lucesole
authors.forename: Giuliana
authors.initials: G
authors.lastname: Leopardi
authors.forename: Barbara
authors.initials: B
authors.lastname: Guiducci
authors.forename: Claudio
authors.initials: C
authors.lastname: Giardini
authors.forename: Alessandro
authors.initials: A
authors.lastname: Isidori
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D017707:Erythrocyte Transfusion; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D019653:Myeloablative Agonists / Q000008:administration & dosage; D017713:Platelet Transfusion; D012010:Red-Cell Aplasia, Pure / Q000209:etiology / Q000628:therapy*; D000069283:Rituximab; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D017086:beta-Thalassemia / Q000150:complications / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists; D000069283:Rituximab